Vandana Rai*
Methylenetetrahydrofolate reductase (MTHFR) is a vital enzyme involved in folate metabolism; a single nucleotide polymorphism (SNP) C677T has been reported to be linked with altered incidences of several diseases. The association between ovary cancer and the MTHFR gene C677T polymorphism has been investigated in several case-control studies. These studies rendered contradictory results, to shed light on these inconclusive findings, a meta-analysis of all available studies relating the C677T polymorphism to the risk of ovary cancer was conducted. The following electronic databases were searched without language restrictions: Pubmed, Google Scholars, Elsevier and Springer Link up to December, 2014. Odds ratios (ORs) with their 95% confidence intervals (95% CIs) were calculated. Meta-analysis was performed using Mix version 1.7. Eleven studies were finally included in present meta-analysis, which contained 5922 individuals with ovary cancer and 5235 healthy controls. There was not significant relationship between MTHFR C677T polymorphism and ovary cancer under allele contrast (OR: 1.05, 95% CI: 0.99-1.11), dominant (OR: 1.02, 95% CI: 0.91-1.13), recessive (OR: 0.99, 95% CI: 0.90-1.08), homozygous (OR: 0.99, 95% CI: 0.86-1.14) and co-dominant/heterozygous (OR: 1.02, 95% CI: 0.91-1.14) genetic models. Subgroup analysis also reached similar results. Sensitivity analysis indicated that the overall result were dependable. In conclusion, results of present meta-analysis showed that MTHFR gene C677T polymorphism is not a risk factor for Ovary cancer.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 